Literature DB >> 1348030

Repertoire of V alpha and V beta regions of T cell antigen receptors on CD4+ and CD8+ peripheral blood T cells in a novel X-linked combined immunodeficiency disease.

A S Goldman1, K H Palkowetz, H E Rudloff, E G Brooks, F C Schmalstieg.   

Abstract

The repertoire of V regions of alpha/beta+ T cell receptor (TcR) on CD4+ and CD8+ T cells from the peripheral blood of six patients with a novel X-linked combined immunodeficiency was investigated by flow cytometry. The relative frequencies of V region subfamilies V alpha 2a on CD4+ T lymphocytes and V beta 5b and V beta 12a on CD8+ T lymphocytes from the peripheral blood from the affected males were decreased significantly. Also, the relative frequencies of certain other V region subfamilies on CD4+ or CD8+ T cells from the peripheral blood of some patients were either considerably below or above the ranges found in normal subjects. Although there may be other explanations including an extrathymic event, we suggest that the abnormalities in the TcR repertoire of peripheral blood T cells are consistent with a dysregulation of the intrathymic maturation/selection of T cells that leads to deficiencies in T cell populations in the peripheral blood of males with this disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348030     DOI: 10.1002/eji.1830220435

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  2 in total

1.  The human T cell receptor V beta repertoire of normal peripheral blood lymphocytes before and after mitogen stimulation.

Authors:  F S Wong; M L Hibberd; L Wen; B A Millward; A G Demaine
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

2.  Missense mutation in exon 7 of the common gamma chain gene causes a moderate form of X-linked combined immunodeficiency.

Authors:  F C Schmalstieg; W J Leonard; M Noguchi; M Berg; H E Rudloff; R M Denney; S K Dave; E G Brooks; A S Goldman
Journal:  J Clin Invest       Date:  1995-03       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.